$20,000 of MODERNA INC. lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Tax Reform - Restoring the Orphan Drug Tax Credit."
You can find more data on corporate lobbying on Quiver Quantitative.
MRNA Congressional Stock Trading
Members of Congress have traded $MRNA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/19 and 1 sale worth up to $15,000 on 08/19.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
MRNA Insider Trading Activity
MRNA insiders have traded $MRNA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:
- STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
- STEPHEN HOGE (President) has made 0 purchases and 5 sales selling 240,583 shares for an estimated $20,618,266.
- JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
- SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
- NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
- ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
MRNA Hedge Fund Activity
We have seen 366 institutional investors add shares of MRNA stock to their portfolio, and 319 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
- D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
- CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
- ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
- BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
MRNA Price Targets
Multiple analysts have issued price targets for $MRNA recently. We have seen 7 analysts offer price targets for $MRNA in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
- Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
- Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
- Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
- Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
- Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
- Eliana Merle from UBS set a target price of $45.0 on 05/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
